MarketInOut Stock Screener Log In | Sign Up

Artiva Biotherapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Artiva Biotherapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization204.85 mln
Float17.82 mln
Earnings Date11/18/2026

Piotroski F-Score

4 / 9
Borderline

1-Year Forecast

20.75
Transformational upside

Relative Strength

4 / 100
Severely lagging

Debt / Equity

0.03
Debt-free

ROE

-55.14
Deeply negative

ROA

-48.96
Deeply negative

Business Description

Artiva Biotherapeutics is a San Diego-based clinical-stage company, founded in 2019, that develops treatments using natural killer cells ? a type of immune cell the body uses to fight disease. Its main therapy, AlloNK, is a ready-to-use cell treatment being studied for a range of autoimmune conditions as well as certain blood cancers. The company is also advancing two additional cell-based treatments aimed at solid tumors, including breast, gastric, and bladder cancers, and at other blood-related cancers.

Key Fundamentals

EPS-3.23
ROE-55.14
ROIC-354
ROA-48.96
EBITDA, mln-88.14
EV / EBITDA2.52
EV / EBIT2.44

Quote Details

Last 4.19
Change -0.04 (-0.95%)
Open 4.20
Volume 1,953,863
Turnover 8,186,686
Average Volume 1,098,411

Financial Ratios

Leverage Ratio1.06
Current Ratio24.16
Price / Book0.60
Price / Tangible Book0.60
Debt / Equity0.03

Financial Strength

Piotroski F-Score 4 / 9
1-Year Target Price20.75
Short Ratio5.00
Short % of Float11.05

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -31.87% 1 / 100   
1 Month -38.29% 8 / 100   
2 Months -59.4% 6 / 100   
6 Months -61.2% 9 / 100   
1 Year -4.56% 42 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog